<DOC>
	<DOCNO>NCT00452335</DOCNO>
	<brief_summary>The primary purpose study evaluate safety efficacy lubiprostone pediatric population constipation , include pharmacokinetics lubiprostone , subset patient .</brief_summary>
	<brief_title>Safety Efficacy Lubiprostone Pediatric Patients With Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Less 18 year age Weight least 12 kg capable swallow capsule Able refrain use medication know treat associate constipation symptom Stable fiber therapy ADHD therapy use medication Patient/Caregiver able complete daily diary Patient able use recommend rectal and/or oral rescue medication need Constipation associate medical , anatomic , physical , organic , condition Hirschsprung 's Disease Nonretentive Fecal Incontinence Untreated fecal impaction impaction require digital manipulation Open gastrointestinal/abdominal surgery laparoscopic surgery investigator discretion Organic bowel disorder , mechanical bowel obstruction , pseudoobstruction , unexplained weight loss Uncontrolled cardiovascular , liver lung disease , neurologic psychiatric disorder , systemic disease , abnormal laboratory test investigator discretion If female , currently pregnant nursing , plan become pregnant nurse clinical study Sexually active male female must utilize acceptable birth control method Prior use lubiprostone , Amitiza , SPI0211 , RU0211</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>